Views & Analysis | Perspectives on pharma industry issues

Oncology

pharmaphorum podcast Episode 286, Kate Estep, Flatiron Health

Closing the global evidence gap in oncology, with Flatiron H...

Kate Estep discusses Flatiron’s AI-powered oncology intelligence platform, Telescope, and how AI tools are changing research decisions.

R&D

Life sciences real estate: Beyond labs

Growth in biotechnology, pharmaceutical R&D, and advanced therapies is driving demand for specialist laboratory space.

R&D

Inspection readiness is now a commercial question

Manufacturers of advanced therapies are discovering that a digital quality system does more than satisfy inspectors.

Digital

Abstract AI concept, turquoise hexagonals on dark background

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

R&D

A certificate of analysis should be evidence, not a sales do...

Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.

White Papers

Sponsored

What is the state of healthcare customer data in pharma? Hav...

Healthcare customer reference data is the fuel that powers pharmaceutical commercial operations.

Patients

Digital therapeutics grow up

Back in January, pharmaphorum caught up with the Syneos Health team to discuss their experience and insights into the emerging category of digital therapeutics (DTx), and the use of softwar

Views & Analysis

Its-time-for-new-language-for-healthcare-marketing

It’s time for new language in healthcare marketing

Healthcare brands need some new terminology and new models.

Sales & Marketing

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.